Nanomedicine-Based Approaches for Treatment of Ocular Diseases

Abstract

Nanomedicine is a new frontier in the treatment of eye diseases with disruptive novelty, from overcoming unique anatomical and physiological barriers that historically impeded drug delivery to the eye. Most ocular diseases, such as glaucoma, AMD, diabetic retinopathy, and uveitis, pose serious challenges to treatment as a result of their complex anatomy and protective mechanisms limiting drug penetration and retention. These old and conventional forms, such as eye drops and ointments, cannot achieve the desired therapeutic concentrations at the target site; hence, efficacy is likely to be compromised and patient compliance will also be poor. Recent nanomedicine-based drug delivery strategies are discussed and applied to ocular drug delivery. Due to their tiny size and large surface area, nanoparticles can carry a variety of therapeutic drugs. Therefore, the solubility and stability of these drugs are much improved. This nanoparticle can serve with controlled and sustained release that enhances bioavailability, thus exhibiting better treatment outcomes. Among these are liposomes, dendrimers, and polymeric nanoparticles; their type shows promise in preclinical as well as clinical studies regarding the treatment of ocular conditions. These liposomes constitute an effective entity because of the biocompatibility of lipid bilayers for the treatment of diseases such as dry eye syndrome and corneal infections, which would allow a mechanism for targeted delivery and sustained release of the drug. Dendrimers, having a highly branched and functionalized surface, do offer an opportunity to control drug targeting and release in diseases such as AMD and glaucoma. The polymeric nanoparticles bearing biodegradable polymers release the drug at a sustained rate with improved stability and have a better prognosis for chronic diseases such as uveitis and diabetic retinopathy. Some of the innovations in nanomedicine encompass drug-eluting contact lenses, sustained-release implants, and gene therapy. The drug-eluting contact lens would serve the purpose of correcting vision by staying in touch with the ocular surface for an even longer period and delivering drugs simultaneously. Some of the sustained-release implants, such as Ozurdex and Retisert, possess the ability to administer long-term drug delivery in chronic conditions with a reduced need for administration throughout the treatment phase. Gene and RNA-based treatments are also gaining ground as potential therapy candidates for the eyes. The concept of gene therapy is that corrective genes are directed delivered into an eye to correct defects in genes causing disease. Others involve interfering with the message of disease-causing genes by using RNAi or introducing specific mRNA strands that introduce new gene expressions.

Keywords

Nanoparticles, Ocular Drug Delivery, Retinal Diseases, Mucoadhesive Nanomedicines, Mucus-Penetrating Nanomedicines, Surface-Modified Nanomedicines, Targeted Therapy, Anti-inflammatory Drugs, Ophthalmic Conditions, Biocompatibility.

Introduction

 

 

 

Clinical Applications

Methods based on nanomedicine have been very promising in the treatment of several ocular diseases. In these novel therapies, the unique properties of nanoparticles are used to heighten drug delivery, optimize therapeutic efficacy, and minimize side effects. A few of the notable clinical applications are as follows:

1. Glaucoma

It's great to see your interest in utilizing nano-particulates for anti-glaucoma drugs. Glaucoma can indeed be challenging to treat, and using particulates to encapsulate anti-glaucoma agents such as timolol or latanoprost for sustained release is a promising approach. Liposomal preparations, among other nanoparticle systems, have shown potential in achieving targeted delivery of the drug to the eye for extended periods of time, which could improve patient compliance with the treatment. This approach holds great promise for enhancing the management of glaucoma.[16]

2. Age-Related Macular Degeneration (AMD)

Nanoparticles for Anti-VEGF Therapy: The growth of abnormal blood vessels within the retina causes AMD, AMD is one of the significant diseases among the elderly causing loss of sight. Most of the anti-VEGF agents, including ranibizumab and aflibercept, have been used for the cure of AMD. It has been presupposed that nanoparticle delivery systems can improve the delivery of agents in a sustained release and thus reduce injections in intravitreal chambers. Some efficacy of polymeric nanoparticles and dendrimers has been ascribed to the prolonged therapeutic effect of the anti-VEGF agents. [17,18]

3. Diabetic Retinopathy

Nanoparticles for Anti-Inflammatory and Anti-VEGF Agents: Diabetic retinopathy results from damage to the blood vessels of the retina secondary to chronic hyperglycemia. The encapsulation of anti-inflammatory and anti-VEGF agents in nanoparticles has a two-tiered approach to the treatment. SLNs have been found to assist in delivering this agent, resulting in reduced inflammation of the retina and preventing the formation of abnormal blood vessels. [19,20]

4. Uveitis

Nanoparticles for Immunosuppressive Drugs: Uveitis is an inflammatory eye disease that affects the uvea and may even lead to blindness, if left untreated. Most commonly utilized immunosuppressive agents are corticosteroids; however, the systemic side effects they induce become problematic. Nanoparticles, such as liposomes and polymeric nanoparticles, permit targeted drug delivery directly to the inflamed tissues; thus, therapeutic efficacy of the drug is maximized without systemic exposure. [21,22]

5. Corneal Diseases

Nanoparticles for Antimicrobial and Anti-Inflammatory Agents: Infection and inflammation of the cornea are very serious, as infection may easily lead to impairment of vision and is therefore sensitive to be treated with localized conditions and less frequent dosing. The delivery of antimicrobial and anti-inflammatory agents can be improved using nanoparticles. Such nanoparticles include nanomicelles and dendrimers with high promise for drug delivery into corneal tissues.[23]

6. Genetic Ocular Diseases

Nanoparticles in Gene Therapy: Specific mutations in certain genes lead to genetic eye diseases, such as retinitis pigmentosa and Leber's congenital amaurosis. Nanoparticles in gene therapy offer the promise of introducing genetic material into cells that would have a modifying effect on them to correct or compensate for faulty genes. Studies using AAV vectors prepared as nanoparticles are exploring whether these carriers can be used to deliver therapeutic genes into the retina.[24]

Case Reports and Clinical Research

1. Liposomal Latanoprost for Glaucoma

• Liposomal latanoprost is presently in a Phase I/II clinical trial for the treatment of glaucoma.
• Liposomal drug delivery of latanoprost gave better IOP control with less frequent dosing than conventional eye drops application.
• The effect of liposome-encapsulated drug delivery was a well-sustained release of the drug, so yielding a better therapeutic effect for the patient, thus giving better compliance and success rates.[25]

2. Polymeric Nanoparticles for AMD

• This Phase III clinical study was designed to ascertain whether polymeric nanoparticles of ranibizumab could be effectively applied in the treatment process for age-related macular degeneration (AMD).
• The results gained from this trial would thus validate the possible application of these nanoparticles as sustained-release formulations administered less frequently with intravitreal injections.
• These nanoparticles ensured that the continuous release of ranibizumab ensured that the drug levels in the retina remained within effective range, thus leading to better outcomes in the treatment process.[26]

3. Solid Lipid Nanoparticles for Diabetic Retinopathy [27-29]

• Promising research on SLNs for the treatment of diabetic retinopathy has been conducted to date.
• These nanoparticles can serve as drug delivery systems for anti-inflammatory and anti-VEGF agents that simultaneously address the two pathologies of the disease
• Results of preclinical studies have already demonstrated that the treatment with SLNs significantly diminishes the inflammatory response and the abnormal vascular growth within the retina, constituting a possible therapeutic application.
• Nanomicelles are investigated for treatment of corneal infections and inflammations.
• Self-assembling colloidal structures can deliver antimicrobial and anti-inflammatory agents directly to the corneal tissues. Clinical studies suggest that nanomicelles can provide site-specific therapy with the reduced rate of dosing frequency, thus decreasing pain to the patient and improving effectiveness of a given treatment.

5. Genetic Ocular Diseases Gene Therapy

• Gene therapy using nanoparticles has shown to be a future promising therapy for genetic ocular diseases, such as retinitis pigmentosa and Leber's congenital amaurosis.
• The AAV vector encapsulated in the nanoparticles have been used to delivered into retinal cells which could mediate the therapeutic gene.
• The clinical trials have shown that the treatment does not only correct the genetic mutation but also allows patients to recover the irreversible retinal function with much hope.
• Such case studies and clinical trials indicate great potential for nanomedicine-based approaches in revolutionizing treatment for ocular diseases. Further development and research in this area would pave the way for a full exploitation of the therapeutic benefits derived from these new modalities. [30-32]

Future Outlook

The field of nanomedicine for ocular diseases is rapidly evolving with some exciting trends and innovation emerging. Many of these developments will soon be introduced to the diagnostic, treatment, and management of ocular conditions, which may change the face of the disease. Some of the key future outlooks in this regard are as follows.

1. Personalized Medicine

Such an addition of nanomedicine will be perfect for personalized medicine, especially in the case of ocular diseases. Personalized medicine involves the tailoring of different treatments toward different patients according to distinct genetic, molecular, and clinical profiles. The help of nanomedicine would add a new dimension to such ocular diseases. The uniqueness of every characteristic about a patient can be analyzed, and nanoparticles can be designed specifically for delivering therapeutic agents tailored to their needs, and it could result in a better treatment with fewer adverse effects. [33,34]

2. Nanomaterials

New nanomaterials with specific properties are in the pipeline, ideas for improvement in biocompatibility and stability along with improving on specific targeting. For instance, thermos-nanoparticles designed such that they can work as both diagnostics and therapy, or theranostics, allowing the simultaneous detection of disease markers and delivery of treatment, that are closely monitored in real-time.[35]

3. Combination Therapies

Nanomedicine enables the co-delivery of different drugs, thus permitting combination therapy to be targeted against different pathways. This might enhance the overall therapeutic effect and avoid drug resistance. An example is nanoparticles that can deliver anti-VEGF agents and corticosteroids in diabetic retinopathy management; both control of angiogenesis and inflammation would be covered.[36]

 4. Integration with Gene Editing Technologies

Gene editing technologies such as CRISPR-Cas9 are promising prospects in the treatment of genetic ocular diseases. Nanoparticles may be used to carry gene editing components that can be targeted to specific cells within the eye. This shall correct the genetic mutations responsible for conditions such as retinitis pigmentosa and Leber's congenital amaurosis, potentially allowing a permanent cure. [37,38]

5. Minimally Invasive Delivery Systems

New research continues to be conducted with the goal of finding minimally invasive delivery systems to bypass the hurdles that have been felt by existing ocular drug delivery techniques. This can be injectable hydrogels, microneedles, or implantable devices that allow for controlled release of nanoparticles for an extended period. Such delivery systems can ensure sustained drug delivery with minimal disruption to the patient.[39]

6. Real-Time Monitoring and Feedback

Future nanomedicine-based treatments can involve real-time monitoring and feedback mechanisms. Nanoparticles may be engineered to carry sensors that detect alterations in the ocular environment and modulate the release of drugs in response to those changes to achieve optimal therapeutic dosing and treatment efficacy.[40]

7. Regulatory and Commercialization Challenges

Nanomedicine still holds great promise for diseases related to the eyes. However, there are quite a few regulatory and commercialization hurdles to be overcome. The safety, efficacy, and quality of nanoparticle-based therapies will be on the agenda. Regulatory agencies will have to set guidelines and standards for the development and approval of such innovative treatments. Manufacturing scalability and cost-effectiveness will also need to be addressed to ensure adoption by the masses. [41,42]

CONCLUSION

Nanomedicine is the transforming approach in ocular diseases' treatment. Instead of providing innovation solutions to some long-standing problems, these therapies enhance bioavailability, targeted delivery, controlled and sustained release, improve therapeutic outcomes, and reduce side effects by exploiting the properties of nanoparticles. In the field of ophthalmology, nanomedicine has shown promise and versatility in curing various ocular conditions, such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and genetic ocular disorders. This is because therapeutic agents can be encapsulated within nanoparticles, which provides new routes in conventional treatments and gene therapy, which revolutionized the field of ophthalmology. In the near future, some promising trends will more significantly revolutionize ocular therapy. There will be personalized medicine to have treatments targeted to an individual patient profile and the advanced nanomaterials and combination therapies that may improve efficacy while reducing resistance. The technology combining gene editing with delivery systems in a nanoparticle is highly promising for the treatment of genetic ocular diseases at the root cause. Other developments will come in delivery systems that are minimally invasive and in real-time monitoring mechanisms that will decrease the discomfort of the patients as well as increase the precision of the treatment. Overall, there is vast promise to be seen in the continued research and development of nanomedicine-based ocular therapies. As it addresses existing drawbacks and pushes the envelope into new discoveries, nanomedicine will improve the management and outcome of ocular diseases tremendously and promises a future of hope and clear vision for sufferers worldwide.

REFRENCES

1. Marchesi N, Fahmideh F, Boschi F, Pascale A, Barbieri A. Ocular neurodegenerative diseases: interconnection between retina and cortical areas. Cells. 2021 Sep 12;10(9):2394.
2. Zhang C, Yan L, Wang X, Zhu S, Chen C, Gu Z, Zhao Y. Progress, challenges, and future of nanomedicine. Nano Today. 2020 Dec 1;35:101008.
3. Tewabe A, Abate A, Tamrie M, Seyfu A, Abdela Siraj E. Targeted drug delivery—from magic bullet to nanomedicine: principles, challenges, and future perspectives. Journal of Multidisciplinary Healthcare. 2021 Jul 5:1711-24.
4. Li S, Chen L, Fu Y. Nanotechnology-based ocular drug delivery systems: recent advances and future prospects. Journal of Nanobiotechnology. 2023 Jul 22;21(1):232.
5. Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: Structure, composition, types, and clinical applications. Heliyon. 2022 May 1;8(5).
6. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011 Aug 26;3(3):1377-97.
7. Abbasi E, Aval SF, Akbarzadeh A, Milani M, Nasrabadi HT, Joo SW, Hanifehpour Y, Nejati-Koshki K, Pashaei-Asl R. Dendrimers: synthesis, applications, and properties. Nanoscale research letters. 2014 Dec;9:1-0.
8. Kamboj S, Bala S, Nair AB. Solid lipid nanoparticles: An effective lipid based technology for poorly water soluble drugs. Int J Pharm Sci Rev Res. 2010 Nov;5(2):78-90.
9. Bose A, Roy Burman D, Sikdar B, Patra P. Nanomicelles: Types, properties and applications in drug delivery. IET nanobiotechnology. 2021 Feb;15(1):19-27.
10. Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020 May 8;25(9):2193.
11. Yusuf A, Almotairy AR, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles’ physicochemical properties on responses in biological systems. Polymers. 2023 Mar 23;15(7):1596.
12. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nature reviews drug discovery. 2021 Feb;20(2):101-24.
13. Fang L, Liu J, Liu Z, Zhou H. Immune modulating nanoparticles for the treatment of ocular diseases. Journal of Nanobiotechnology. 2022 Nov 24;20(1):496.
14. Mollé LM, Smyth CH, Yuen D, Johnston AP. Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2022 Nov;14(6):e1809.
15. Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomedical Technology. 2024 Mar 1;5:109-22.
16. Joseph TM, Kar Mahapatra D, Esmaeili A, Piszczyk ?, Hasanin MS, Kattali M, Haponiuk J, Thomas S. Nanoparticles: Taking a unique position in medicine. Nanomaterials. 2023 Jan 31;13(3):574.
17. Xu M, Fan R, Fan X, Shao Y, Li X. Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis. Drug design, development and therapy. 2023 Dec 31:3241-62.
18. Seah I, Zhao X, Lin Q, Liu Z, Su SZ, Yuen YS, Hunziker W, Lingam G, Loh XJ, Su X. Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. Eye. 2020 Aug 1;34(8):1341-56.
19. Wei J, Mu J, Tang Y, Qin D, Duan J, Wu A. Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy. Journal of nanobiotechnology. 2023 Aug 19;21(1):282.
20. Tawfik M, Chen F, Goldberg JL, Sabel BA. Nanomedicine and drug delivery to the retina: Current status and implications for gene therapy. Naunyn-schmiedeberg's Archives of Pharmacology. 2022 Dec;395(12):1477-507.
21. Taylor AW. Ocular immunosuppressive microenvironment. Immune Response and the Eye. 2007;92:71-85.
22. Liu Y, Xu H, Yan N, Tang Z, Wang Q. Research progress of ophthalmic preparations of immunosuppressants. Drug Delivery. 2023 Dec 31;30(1):2175925.
23. Lv X, Min J, Huang J, Wang H, Wei S, Huang C, Dai J, Chen Z, Zhou H, Xu Y, Zhao H. Simultaneously Controlling Inflammation and Infection by Smart Nanomedicine Responding to the Inflammatory Microenvironment. Advanced Science. 2024:2403934.
24. Wang T, Yu T, Liu Q, Sung TC, Higuchi A. Lipid nanoparticle technology-mediated therapeutic gene manipulation in the eyes. Molecular Therapy-Nucleic Acids. 2024 Sep 10;35(3).
25. Longing J. What's New in the Glaucoma Drug and Surgical Device Pipeline for 2023 and Beyond?.
26. Yang B, Li G, Liu J, Li X, Zhang S, Sun F, Liu W. Nanotechnology for age-related macular degeneration. Pharmaceutics. 2021 Nov 29;13(12):2035.
27. Pandey S, Shaikh F, Gupta A, Tripathi P, Yadav JS. A recent update: solid lipid nanoparticles for effective drug delivery. Advanced Pharmaceutical Bulletin. 2021 May 16;12(1):17-33.
28. Tawfik M, Chen F, Goldberg JL, Sabel BA. Nanomedicine and drug delivery to the retina: Current status and implications for gene therapy. Naunyn-schmiedeberg's Archives of Pharmacology. 2022 Dec;395(12):1477-507.
29. Wang Z, Zhang N, Lin P, Xing Y, Yang N. Recent advances in the treatment and delivery system of diabetic retinopathy. Frontiers in Endocrinology. 2024 Feb 15;15:1347864.
30. Amato A, Arrigo A, Aragona E, Manitto MP, Saladino A, Bandello F, Battaglia Parodi M. Gene therapy in inherited retinal diseases: an update on current state of the art. Frontiers in Medicine. 2021 Oct 15;8:750586.
31. Drag S, Dotiwala F, Upadhyay AK. Gene therapy for retinal degenerative diseases: progress, challenges, and future directions. Investigative Ophthalmology & Visual Science. 2023 Jun 1;64(7):39-.
32. Choi EH, Suh S, Sears AE, Ho?ubowicz R, Kedhar SR, Browne AW, Palczewski K. Genome editing in the treatment of ocular diseases. Experimental & molecular medicine. 2023 Aug;55(8):1678-90.
33. Noury M, Lopez J. Nanomedicine and personalised medicine: understanding the personalisation of health care in the molecular era. Sociology of Health & Illness. 2017 May;39(4):547-65.
34. Fornaguera C, García-Celma MJ. Personalized nanomedicine: a revolution at the nanoscale. Journal of personalized medicine. 2017 Oct 12;7(4):12.
35. Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. Journal of hematology & oncology. 2021 Dec;14:1-27.
36.  Wang H, Huang Y. Combination therapy based on nano codelivery for overcoming cancer drug resistance. Medicine in drug discovery. 2020 Jun 1;6:100024.
37. Deneault E. Recent Therapeutic Gene Editing Applications to Genetic Disorders. Current Issues in Molecular Biology. 2024 Apr 30;46(5):4147-85.
38. Hirakawa MP, Krishnakumar R, Timlin JA, Carney JP, Butler KS. Gene editing and CRISPR in the clinic: current and future perspectives. Bioscience reports. 2020 Apr;40(4):BSR20200127.
39. Zhu D, Li Z, Huang K, Caranasos TG, Rossi JS, Cheng K. Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair. Nature communications. 2021 Mar 3;12(1):1412.
40. Han Q, Niu M, Wu Q, Zhong H. Real-time Monitoring of Nanoparticle-based Therapeutics: A Review. Current Drug Metabolism. 2018 Feb 1;19(2):124-30.
41. Ali F, Neha K, Parveen S. Current regulatory landscape of nanomaterials and nanomedicines: A global perspective. Journal of Drug Delivery Science and Technology. 2023 Feb 1;80:104118..
42. Thapa RK, Kim JO. Nanomedicine-based commercial formulations: Current developments and future prospects. Journal of Pharmaceutical Investigation. 2023 Jan;53(1):19-33.